Skip to main content

Table 1 Oral selexipag doses and their corresponding IV selexipag doses

From: Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Oral selexipag dose, µg bid

IV selexipag dose, µg bid

Number of patients at dose level, n (%)

200

225

0

400

450

1 (5.0)

600

675

2 (10.0)

800

900

2 (10.0)

1000

1125

3 (15.0)

1200

1350

2 (10.0)

1400

1575

1 (5.0)

1600

1800

9 (45.0)

  1. bid twice daily, IV intravenous